Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun;31 Suppl 2(Suppl 2):e13605.
doi: 10.1111/nmo.13605.

Management of cyclic vomiting syndrome in adults: Evidence review

Ravi N Sharaf  1 , Thangam Venkatesan  2 , Raj Shah  3 , David J Levinthal  4 , Sally E Tarbell  5 , Safwan S Jaradeh  6 , William L Hasler  7 , Robert M Issenman  8 , Kathleen A Adams  9 , Irene Sarosiek  10 , Christopher D Stave  11 , B U K Li  12 , Shahnaz Sultan  13
Affiliations
Review

Management of cyclic vomiting syndrome in adults: Evidence review

Ravi N Sharaf et al. Neurogastroenterol Motil. 2019 Jun.

Abstract

Background: This evidence review was conducted to inform the accompanying clinical practice guideline on the management of cyclic vomiting syndrome (CVS) in adults.

Methods: We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework and focused on interventions aimed at prophylactic management and abortive treatment of adults with CVS. Specifically, this evidence review addresses the following clinical questions: (a) Should the following pharmacologic agents be used for prophylaxis of CVS: amitriptyline, topiramate, aprepitant, zonisamide/levetiracetam, or mitochondrial supplements? (b) Should the following pharmacologic agents be used for abortive treatment: triptans or aprepitant?

Results: We found very low-quality evidence to support the use of the following agents for prophylactic and abortive treatment of CVS: amitriptyline, topiramate, aprepitant, zonisamide/levetiracetam, and mitochondrial supplements. We have moderate certainty of evidence for the use of triptans as abortive therapy. We found limited evidence to support the use of ondansetron and the treatment of co-morbid conditions and complementary therapies.

Conclusions: This evidence review helps inform the accompanying guideline for the management of adults with CVS which is aimed at helping clinicians, patients, and policymakers, and should improve patient outcomes.

Keywords: cyclic vomiting; technical review; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flow diagram
See this image and copyright information in PMC

References

    1. Abu‐Arafeh I, Russell G. Cyclical vomiting syndrome in children: a population‐based study. J Pediatr Gastroenterol Nutr. 1995;21:454‐458. - PubMed
    1. Sagar RC, Sood R, Gracie DJ, et al. Cyclic vomiting syndrome is a prevalent and under‐recognized condition in the gastroenterology outpatient clinic. Neurogastroenterol Motil. 2018;30:. - PubMed
    1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924‐926. - PMC - PubMed
    1. Aanpreung P, Vajaradul C. Cyclic vomiting syndrome in Thai children. J Med Assoc Thai. 2002;85(Suppl 2):S743‐S748. - PubMed
    1. Andersen JM, Sugerman KS, Lockhart JR, Weinberg WA. Effective prophylactic therapy for cyclic vomiting syndrome in children using amitriptyline or cyproheptadine. Pediatrics. 1997;100:977‐981. - PubMed

Publication types

Supplementary concepts